$1.48
0.01% yesterday
Nasdaq, May 20, 09:44 pm CET
ISIN
US88875G1013
Symbol
TLSA
Sector
Industry

Tiziana Life Sciences PLC Sponsored ADR Stock price

$1.50
+0.37 32.74% 1M
+0.50 50.00% 6M
+0.80 115.46% YTD
+0.73 94.81% 1Y
+0.64 74.42% 3Y
-0.37 19.99% 5Y
-0.15 8.96% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.02 1.35%
ISIN
US88875G1013
Symbol
TLSA
Sector
Industry

Key metrics

Market capitalization $167.19m
Enterprise Value $149.44m
EV/FCF (TTM) EV/FCF negative
Short interest 1.23%

Is Tiziana Life Sciences PLC Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Tiziana Life Sciences PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Tiziana Life Sciences PLC Sponsored ADR:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Tiziana Life Sciences PLC Sponsored ADR:

Buy
100%

Financial data from Tiziana Life Sciences PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '22
+/-
%
- -
-
100%
- Direct Costs 0.05 0.05
-
-
-0.05 -0.05
-
-
- Selling and Administrative Expenses 4.71 4.71
-
-
- Research and Development Expense 13 13
-
-
-18 -18
-
-
- Depreciation and Amortization 0.05 0.05
-
-
EBIT (Operating Income) EBIT -18 -18
62% 62%
-
Net Profit -15 -15
-
-

In millions USD.

Don't miss a Thing! We will send you all news about Tiziana Life Sciences PLC Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tiziana Life Sciences PLC Sponsored ADR Stock News

Positive
Proactive Investors
6 days ago
Tiziana Life Sciences Ltd (NASDAQ:TLSA)' investigational therapy intranasal foralumab has been shown to significantly reduce neuroinflammation in a 78-year-old patient with moderate Alzheimer's disease (AD), a newly published study has shown. The study, published in the Journal of Clinical Nuclear Medicine, was led by Dr Tarun Singhal and Dr Howard Weiner of Brigham and Women's Hospital, a foun...
Neutral
GlobeNewsWire
9 days ago
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr.
Positive
Proactive Investors
12 days ago
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Friday that a patient with moderate Alzheimer's disease showed a marked reduction in brain inflammation after three months of treatment with its lead drug candidate, intranasal foralumab, under an expanded access program. A PET scan revealed a significant decrease in microglial activation—an indicator of neuroinflammation linked to Alzheimer's pro...
More Tiziana Life Sciences PLC Sponsored ADR News

Company Profile

Tiziana Life Sciences Plc is a biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. Its lead product candidate in immunology is Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody. The company was founded by Gabriele Marco Antonio Cerrone on November 4, 2013 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Ivor Elrifi
Founded 1998
Website www.tizianalifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today